Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The pharmacology of neonatal resuscitation and cardiopulmonary intensive care Part II--Extended intensive care Benitz WE; Frankel LR; Stevenson DKWest J Med 1986[Jul]; 145 (1): 47-51An optimal outcome for a distressed newborn infant can be achieved only if immediate resuscitation is followed by appropriate cardiopulmonary intensive care. In the preceding article in this series, we provided recommendations for drug therapy during the initial resuscitation. When an infant is stable enough for transfer to an intensive care nursery, extended cardiopulmonary intensive care should be initiated. If the infant remains distressed, this may require drug therapy to improve cardiac output, either by enhancing cardiac performance (dopamine, dobutamine or epinephrine) or by reducing afterload (nitroprusside). Drugs that alter the distribution of the circulation may be required for infants with persistent hypoxemia due to pulmonary hypertension or congenital heart disease (tolazoline, nitroprusside, prostaglandin E(1)), or with pulmonary congestion due to persistent patency of the ductus arteriosus (indomethacin). Infants with pulmonary disease may benefit from administration of agents that alter pulmonary function (furosemide, nitroprusside or neuromuscular blockers). Finally, treatment of the underlying disorder, with antibiotics or naloxone, for example, must not be neglected.|*Intensive Care Units, Neonatal[MESH]|*Resuscitation[MESH]|Alprostadil/pharmacology[MESH]|Cardiac Output/drug effects[MESH]|Coronary Circulation/drug effects[MESH]|Ductus Arteriosus/drug effects[MESH]|Humans[MESH]|Indomethacin/pharmacology[MESH]|Infant, Newborn[MESH]|Infant, Newborn, Diseases/physiopathology/*therapy[MESH]|Nitroprusside/pharmacology[MESH]|Pulmonary Circulation/drug effects[MESH]|Pulmonary Gas Exchange/drug effects[MESH]|Sympathomimetics/pharmacology[MESH]|Tolazoline/pharmacology[MESH]|Vascular Resistance/drug effects[MESH] |